Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

Chemours Company (NYSE:CC) is not having a great start to its life as an independent, publicly-traded company. Shares of the company, which was once the performance chemicals arm of E I Du Pont De Nemours And Co (NYSE:DD) fell to as low as $13.20 per share earlier today, or 11.94% lower than its closing price of $14.99 per share yesterday. The slide of the stock appears to be due to a generally pessimistic outlook on the company and its niche industry. JP Morgan was among the first firms to reveal its negative stance on the company. The firm said before the spin-off was completed that its regards the transaction as dilutive to parent company E I Du Pont De Nemours And Co (NYSE:DD), which it said will lose about $978 million in operating income, or $900 million after adjusting for an estimated $75 million in residual costs. JP Morgan has an ‘Underweight’ rating on Chemours Company (NYSE:CC). Credit Suisse is also pessimistic about Chemours. The financial firm said that Chemours could possibly be hounded by legal problems it took with it from DuPont. There is a possibility that environmental fines of $295 million will double, Credit Suisse said. Early on, we have also predicted here at Insider Monkey that Chemours’ chances of matching the success of fellow DuPont spin-off Axalta Coating Systems Ltd (NYSE:AXTA) are not at all likely.

At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically delivered a monthly alpha of six basis points, though these stocks underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning over 135% and beating the market by more than 80 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise rather than large-cap stocks.

Not everyone agrees with this, however, as other analysts are not recommending selling shares of the former DuPont division. UBS initiated coverage on Chemours Company (NYSE:CC) on Monday with a ‘Neutral’ rating and a price target of $16.00. Nonetheless, the ‘Neutral’ rating comes with a caveat. UBS said that the initial $100 million per quarter dividend of the company will likely be slashed to a “more sustainable” $50 million per quarter level. The firm, according to UBS’s analysis, will likely not be able to generate sufficient cash flow to fund the announced dividend.

Barclays, on the other hand, is not putting too much weight into whether or not Chemours Company (NYSE:CC) will even pay a dividend. With or without a dividend, Barclays believes the performance chemicals firm will gain 50%. Barclays initiated coverage on Monday with a rating of ‘Overweight’ on Chemours, and a price target of $24.00 per share. Explaining the bullish stand, analyst Duffy Fischer said that there are “few quality assets” in the industry Chemours is in “that trade meaningfully below asset value”. This makes Chemours, he wrote in a note, “a unique opportunity.” In his note, he added that Barclays values Chemours’ titanium dioxide business at $38 per share, its Fluoro products businesses at $17 per share and its Chemical Solutions business at $4 per share. Adjusting for net debt of $20 per share, corporate expenses of $5 per share and environmental expenses of $5 per share, the equity to owners is at $29 per share, Fischer wrote.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.

Subscribe me to Insider Monkey's Free Daily Newsletter

This is a FREE report from Insider Monkey. Credit Card is NOT required.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.